Leap Therapeutics Newsroom

Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials

TipRanksMay 16 04:19 ET

Leap Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Leap Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 14 08:00 ET

Express News | HC Wainwright & Co. Maintains Buy on Leap Therapeutics, Lowers Price Target to $5.5

BenzingaMay 14 07:49 ET

Leap Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 97.13% HC Wainwright & Co. $7 → $5.5 Maintains Buy 03/19/2024 222.58% Baird $11 → $9 Maintains

BenzingaMay 14 07:48 ET

Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress

Yahoo FinanceMay 13 08:31 ET

Express News | Leap Therapeutics Says Net Proceeds From April 2024 $37.2M Financing, Combined With Existing Cash, Cash Equivalents And Marketable Securities Of $54.9M, Are Expected To Provide Cash Runway Into The Second Quarter Of 2026

BenzingaMay 13 07:11 ET

Express News | Leap Therapeutics Q1 2024 GAAP EPS $(0.51) Beats $(0.58) Estimate

BenzingaMay 13 07:09 ET

Express News | Leap Therapeutics Inc Q1 Shr View $-0.59 -- Lseg Ibes Data

ReutersMay 13 07:03 ET

Express News | Leap Therapeutics Inc Qtrly Shr Loss $ 0.51

ReutersMay 13 07:03 ET

Express News | Leap Therapeutics Q1 Net Income USD -13.82 Million

ReutersMay 13 07:00 ET

Express News | Leap Therapeutics Q1 Operating Expenses USD 14.825 Million

ReutersMay 13 07:00 ET

Leap Therapeutics 1Q Loss/Shr 51c >LPTX

Leap Therapeutics 1Q Loss/Shr 51c >LPTX

Dow JonesMay 13 07:00 ET

Leap Therapeutics | 10-Q: Quarterly report

SEC announcementMay 13 06:53 ET · Announcements

Leap Therapeutics Reports First Quarter 2024 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.

Leap TherapeuticsMay 13 00:00 ET

Express News | Leap Therapeutics Inc Files for Resale of up to 14.2 Mln Common Shares by the Selling Stockholders - SEC Filing

ReutersMay 10 17:03 ET

Express News | Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024

Moomoo 24/7Apr 19 16:43 ET

Express News | Gilead Sciences, Inc Reports 13.9% Passive Stake in Leap Therapeutics as of April 10- SEC Filing

Moomoo 24/7Apr 19 16:33 ET

Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler

Seeking AlphaApr 12 11:34 ET

Express News | Leap Therapeutics Shares Are Trading Higher After the Company Announced a $40 Million Private Placement

Moomoo 24/7Apr 11 09:16 ET

Express News | Leap Therapeutics Inc: Intends to Use Net Proceeds From Financing to Fund Continued Development of Its Lead Monoclonal Antibody Program, Dkn-01

Moomoo 24/7Apr 11 08:31 ET